Group 1 - The company has completed multiple batches of pilot production for continuous glucose monitoring (CGM) devices and is actively conducting clinical-related work domestically [1] - The company is also advancing the research and development of CGM products for international markets [1] - The CGM product will be integrated into a new "O+O" model for diabetes diagnosis and care, which is expected to accelerate the implementation and development of the company's core strategy [1] Group 2 - The company aims to create a high-frequency, sticky customer base through effective service in the "O+O" model, which can generate good synergy effects [1]

（文章来源：每日经济新闻） 九安医疗（002432.SZ）9月9日在投资者互动平台表示，截至目前公司已完成首期10.5亿元中期票据的 发行工作，年化利率为1.83%，本次债券的成功发行，拓宽了公司融资渠道，优化了负债结构和财务成 本。首期中期票据的募集资金用途为偿还有息负债、科技创新领域的研发支出和补充流动资金，公司将 根据实际用途情况，严格按照银行间市场交易商协会的相关监管要求，统筹安排本次募集资金的使用。 每经AI快讯，有投资者在投资者互动平台提问：请问科技创新债中期票据目前工作进展到什么阶段？ ...

Core Viewpoint - The company has completed multiple batches of trial production in the continuous glucose monitoring (CGM) field and is actively conducting domestic testing and clinical work while advancing the development of CGM products for international markets [1] Group 1: Product Development - The company is focusing on the development of CGM products, which are crucial for diabetes management [1] - The CGM products will be integrated into a new "O+O" model for diabetes diagnosis and care, enhancing the company's core strategic implementation and development [1] Group 2: Market Strategy - The company aims to deepen its service in the "O+O" model, which is expected to create high-frequency customer engagement and generate synergistic effects [1]

Group 1 - The company has completed multiple batches of trial production for Continuous Glucose Monitoring (CGM) devices and is actively conducting domestic testing and clinical work [2] - The company is also advancing the research and development of CGM products for international markets [2] - The CGM product will be integrated into a new "Online + Offline" (O+O) model for diabetes care, which is expected to accelerate the implementation of the company's core strategy and development [2] Group 2 - The company aims to create a high-frequency, sticky customer base through effective engagement and deep service in the O+O model, which could lead to good synergy effects [2]

Group 1 - The company has invested in a fund called TianKai JiuAn HaiHe HaiTang Sci-Tech Mother Fund with a total investment of 5 billion RMB, contributing up to 3.56 billion RMB or equivalent in USD [2] - The fund has invested 100 million RMB in MuXi Technology, and the company's shareholding in MuXi is minimal, indicating it will not significantly impact the company's operational performance [2] - The company's management discussion and analysis in the 2025 semi-annual report includes information on collaboration with professional investors for joint investments and direct investment activities [2]

Core Viewpoint - Ji'an Medical's stock price has shown fluctuations, with a slight increase of 2.02% on September 8, 2023, while the company faces a decline in revenue but an increase in net profit year-on-year [1][2]. Company Overview - Ji'an Medical, established on August 22, 1995, and listed on June 10, 2010, is located in Tianjin and specializes in the research, production, and sales of home medical health electronic products [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [1]. Financial Performance - For the first half of 2025, Ji'an Medical reported a revenue of 765 million yuan, a year-on-year decrease of 43.35%, while the net profit attributable to shareholders reached 920 million yuan, reflecting a year-on-year increase of 52.91% [2]. - Cumulatively, the company has distributed 1.794 billion yuan in dividends since its A-share listing, with 1.39 billion yuan distributed over the past three years [3]. Shareholder Information - As of August 10, 2025, the number of Ji'an Medical shareholders increased to 73,000, with an average of 6,491 circulating shares per person, a decrease of 2.19% from the previous period [2]. - The top ten circulating shareholders include notable ETFs, with the Huabao Zhongzheng Medical ETF holding 10.9885 million shares, a decrease of 1.836 million shares from the previous period [3].

Group 1 - The company held its 25th meeting of the 6th Board of Directors on September 5, 2025, with all 6 directors present, complying with legal and statutory requirements [1][2] - The Board approved a proposal to change the purpose of 9,771,882 shares originally intended for maintaining company value and shareholder rights to be used for cancellation and reduction of registered capital [1][2] - The proposal for share cancellation requires approval from the shareholders' meeting, and the Board has requested authorization for management to handle the related procedures [2] Group 2 - The company plans to hold its third extraordinary shareholders' meeting on September 22, 2025, combining in-person and online voting [2]

Core Viewpoint - The company has approved a proposal to change the purpose of part of the repurchased shares and to cancel them, which aligns with relevant regulations and does not harm the interests of the company or its shareholders [1][2]. Group 1: Meeting Details - The sixth session of the 20th meeting of the Supervisory Board was held on September 5, 2025, with all three attending supervisors present [1]. - The meeting was chaired by Mr. Yao Kai, the chairman of the Supervisory Board, and complied with the legal and regulatory requirements [1]. Group 2: Proposal Approval - The proposal to change the purpose of part of the repurchased shares and to cancel them was approved with a unanimous vote of 3 in favor, 0 against, and 0 abstentions [1]. - The Supervisory Board concluded that the change complies with the regulations regarding share repurchase and does not negatively impact the company's financial, operational, research, or debt obligations [1]. Group 3: Impact on Company - The cancellation of the repurchased shares will not affect the company's control or its compliance with listing conditions, ensuring that the company's listing status remains intact [1]. - The proposal is subject to approval by the shareholders' meeting before implementation [2].

Group 1 - The company announced the approval of a proposal to change the purpose of part of the repurchased shares and to cancel them [2] - The company also approved a proposal to hold the third extraordinary general meeting of shareholders in 2025 [2]

Core Points - The company announced the approval of a proposal to change the purpose of part of the repurchased shares and to cancel them [2] Group 1 - The sixth session of the company's supervisory board held its twentieth meeting [2] - The proposal regarding the change in the use of repurchased shares was reviewed and approved [2]